VERAXA Biotech Presented In Vivo Cancer Drug Results
New dual-targeting ADC technology demonstrated tumor regression in preclinical models during the World ADC Congress.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Is the development of safer, more precise cancer treatments moving fast enough for patients?
VERAXA Biotech has presented proof-of-concept data for its BiTAC-ADC technology at the 17th World ADC Congress. The study demonstrated tumor regression in a xenograft breast cancer model using the novel dual-targeting approach.
Why it matters
This strategy aims to improve cancer treatment safety by preventing the release of active toxins in the systemic periphery. By requiring co-targeting at the tumor site, the platform seeks to minimize off-target effects.
The BiTAC-ADC platform utilizes a 3 mg/kg single dose to achieve tumor regression in xenograft breast cancer models. Researchers observed no decrease in body weight, suggesting an absence of systemic toxicity compared to conventional single-target ADCs.
The players
VERAXA Biotech
A Zurich-based firm developing antibody-drug conjugates and bispecific technologies for targeted cancer therapies.
The details
BiTAC-ADC technology uses two complementary, systemically inactive prodrugs that remain inert until they reach the tumor site. Each component targets a specific tumor-associated antigen. The therapeutic toxin is only released once both antibodies internalize into the tumor cell, effectively localizing the treatment to the malignant tissue.
Timeline
October 13, 2026: VERAXA Biotech presented data at the World ADC Congress.
The Tech Race
This development marks a shift from conventional single-target Antibody-Drug Conjugates toward dual-targeting architectures. The race to minimize systemic toxicity remains the primary hurdle for the next generation of ADC platform designs.
The technology is currently in the research-stage, meaning it is not yet available for clinical use. Future developments will focus on pipeline advancement into human clinical trials to establish efficacy and safety.
The takeaway
VERAXA Biotech is moving toward clinical development of its dual-targeting prodrug platform. Interested observers should monitor future corporate announcements regarding the timeline for the first human trials of the BiTAC-ADC format.
Further reading
For more on the current landscape of cancer drug research, visit Biotech.
Live Poll
Is the development of safer, more precise cancer treatments moving fast enough for patients?
